• rechercheur

    What we do

The PDC Foundation provides leadership and identifies innovations in all fields that contribute to the sustainable control of dengue.

We champion an integrated approach

PDC was the first organization to adopt a holistic approach based on combining vaccination and vector control strategies. These strategies complement and enhance one another to provide a more powerful tool against dengue than either one alone.

We promote cross-fertilization

At the interface between several disciplines, PDC promotes cross-fertilization to develop pioneering strategies that advance dengue control and prevention. Since it was founded in 2013, PDC has created unprecedented opportunities for scientists hailing from different fields to leverage their combined expertise and fill important knowledge gaps.

We tackle tough questions in the field of dengue research

Our taskforces, workshops and publications address questions such as:

  • How does vector control impact dengue epidemiology?
  • What is the relationship between mosquito density and disease incidence?
  • What are the most promising tools in the development pipeline?
  • What is the most effective way to measure synergies between vector control methods?

Gathering evidence about the impact of integrating vector control and vaccination interventions and quantifying this impact is one of PDC’s primary roles.

Our taskforces

PDC taskforces are think tanks where leading experts identify and assess new developments, draft recommendations and suggest topics for PDC-sponsored workshops.

For example, our Taskforce on Vector Control has delivered key outcomes about the most effective vector control methods, critical endpoints for clinical trials, and the design of trials to assess synergies between vector control and vaccination for the prevention of human dengue disease.

Our initiatives

Through PDC taskforces, workshops, scientific publications, advocacy and video campaigns, we design and implement initiatives that bring us closer to the goal of sustainable dengue control and prevention.

Our 3 workstreams

Our triple focus encompasses 3 major workstreams: dengue prevention through vector control, dengue prevention through vaccination, and dengue surveillance.

Vector control

Vector control has proven to be effective in controlling other mosquito-borne diseases, but to date its impact on dengue disease incidence has not been measured.

Some of the key questions and challenges in vector control today include:

  • What are the best vector control methods available today?
  • What tools are most effective to measure the impact of vector control on disease incidence?
  • How should clinical studies be designed to assess the efficacy of vector control?

To answer these questions we organized workshops on vector control in 2013 – 2015:

Workshops on vector control

  • 2013: A Critical Assessment of Vector Control for Dengue Prevention
    This meeting provided a “state of the art” assessment of current and future vector control methods. It identified knowledge gaps to be addressed in order to accurately evaluate synergies between vaccination and vector control.
  • 2015: Developing a Research Agenda for Assessing Vector Control to Prevent Dengue

    The 2015 workshop provided answers to some questions raised at the 2013 meeting. Participants agreed on the importance of using epidemiological rather than entomological outcomes for field trials, as well as the best design for clinical studies (randomized controlled trials). They concluded that indoor residual spraying associated with larva control has the most powerful impact on dengue incidence.


In 2016, the first dengue vaccine was launched in three countries. Since then, results have been encouraging, yet they also raise critical questions. For instance, why does the vaccine show strong efficacy against severe forms of dengue and poor efficacy in people who have never been infected by the virus?

PDC seeks to address these and other fundamental questions about how the immune system reacts after infection with the virus and after vaccination.

The Strategic Advisory Group of Experts (SAGE) recommendations highlight the need for countries to have sero-epidemiological evidence before introducing the dengue vaccine, which is not only complex but also challenging in terms of feasibility.

A practical, consensus-based research agenda has been defined based on using existing cohorts to better address the immunology of dengue, the pathogenesis of severe forms, and the definition of the correlates of protection.

Workshops on vaccines


Disease surveillance to date has been designed to detect outbreaks but not to measure the impact of vaccine and vector control interventions. With a changing surveillance landscape and the recent introduction of the dengue vaccine, methods must be brought up to speed to accurately assess the burden of disease and the impact of interventions.

In most areas, dengue surveillance relies on passive systems based on physician reporting and case counts that are only partially confirmed by laboratory tests. Such systems have considerable limitations, including poor sensitivity caused by delays between case occurrence and reporting, under-reporting, and insufficient serological and virological diagnosis.

New surveillance tools in the pipeline are expected to overcome the limitations of current methods.

Dengue diagnostic tests must be reliable and affordable for use in resource-limited settings while providing sufficient sensitivity and specificity. This is essential for patients as well as for vaccine and epidemiological studies.

Workshops on surveillance


Reports outlining conclusions of PDC workshops along with expert recommendations, actionable items and takeaway messages:

A critical assessment of vector control for dengue prevention

The partnership for dengue control – a new global alliance for the prevention and control of dengue.